These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34960240)

  • 21. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.
    Itzhaki Ben Zadok O; Shaul AA; Ben-Avraham B; Yaari V; Ben Zvi H; Shostak Y; Pertzov B; Eliakim-Raz N; Abed G; Abuhazira M; Barac YD; Mats I; Kramer MR; Aravot D; Kornowski R; Ben-Gal T
    Eur J Heart Fail; 2021 Sep; 23(9):1555-1559. PubMed ID: 33963635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral response among patients with interstitial lung disease vaccinated with the BNT162b2 SARS-Cov-2 vaccine: a prospective cohort study.
    Pertzov B; Shmueli E; Ben Zvi H; Massarweh A; Barkan T; Ness A; Shostak Y; Freidkin L; Shtraichman O; Kramer MR
    Respir Res; 2022 Sep; 23(1):226. PubMed ID: 36045374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
    Massarweh A; Eliakim-Raz N; Stemmer A; Levy-Barda A; Yust-Katz S; Zer A; Benouaich-Amiel A; Ben-Zvi H; Moskovits N; Brenner B; Bishara J; Yahav D; Tadmor B; Zaks T; Stemmer SM
    JAMA Oncol; 2021 Aug; 7(8):1133-1140. PubMed ID: 34047765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effect of Gestational Age at BNT162b2 mRNA Vaccination on Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Levels.
    Rottenstreich A; Zarbiv G; Oiknine-Djian E; Vorontsov O; Zigron R; Kleinstern G; Wolf DG; Porat S
    Clin Infect Dis; 2022 Aug; 75(1):e603-e610. PubMed ID: 35171998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of post-vaccination immunoglobulin G antibodies and T-cell immune response after inoculation with different types and doses of SARS-CoV-2 vaccines: A retrospective cohort study.
    Al-Rifai RH; Alhosani F; Abuyadek R; Atef S; Donnelly JG; Leinberger-Jabari A; Ahmed LA; Altrabulsi B; Alatoom A; Alsuwaidi AR; AbdelWareth L
    Front Med (Lausanne); 2022; 9():1092646. PubMed ID: 36703898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination.
    Salvagno GL; Henry BM; di Piazza G; Pighi L; De Nitto S; Bragantini D; Gianfilippi GL; Lippi G
    Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34064509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
    Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
    Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E;
    Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
    Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
    PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
    Lasagna A; Agustoni F; Percivalle E; Borgetto S; Paulet A; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Lilleri D; Secondino S; Falzoni M; Schiavo R; Klersy C; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2021 Oct; 6(5):100272. PubMed ID: 34543863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination.
    Young BE; Seppo AE; Diaz N; Rosen-Carole C; Nowak-Wegrzyn A; Cruz Vasquez JM; Ferri-Huerta R; Nguyen-Contant P; Fitzgerald T; Sangster MY; Topham DJ; Järvinen KM
    JAMA Pediatr; 2022 Feb; 176(2):159-168. PubMed ID: 34757387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers.
    Decru B; Van Elslande J; Steels S; Van Pottelbergh G; Godderis L; Van Holm B; Bossuyt X; Van Weyenbergh J; Maes P; Vermeersch P
    Front Immunol; 2022; 13():909910. PubMed ID: 35784321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose.
    Sanna G; Marongiu A; Firinu D; Piras C; Palmas V; Galdiero M; Atzori L; Caria P; Campagna M; Perra A; Costanzo G; Coghe F; Littera R; Chessa L; Manzin A
    Clin Exp Med; 2024 Jan; 24(1):12. PubMed ID: 38244064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.
    Fraley E; LeMaster C; Geanes E; Banerjee D; Khanal S; Grundberg E; Selvarangan R; Bradley T
    BMC Med; 2021 Jul; 19(1):169. PubMed ID: 34304742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
    Monin L; Laing AG; Muñoz-Ruiz M; McKenzie DR; Del Molino Del Barrio I; Alaguthurai T; Domingo-Vila C; Hayday TS; Graham C; Seow J; Abdul-Jawad S; Kamdar S; Harvey-Jones E; Graham R; Cooper J; Khan M; Vidler J; Kakkassery H; Sinha S; Davis R; Dupont L; Francos Quijorna I; O'Brien-Gore C; Lee PL; Eum J; Conde Poole M; Joseph M; Davies D; Wu Y; Swampillai A; North BV; Montes A; Harries M; Rigg A; Spicer J; Malim MH; Fields P; Patten P; Di Rosa F; Papa S; Tree T; Doores KJ; Hayday AC; Irshad S
    Lancet Oncol; 2021 Jun; 22(6):765-778. PubMed ID: 33930323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.